F ate Therapeutics (NASDAQ:FATE) stock closed 12% higher Monday after soaring as much as 73% on news that the first patient in the company's Phase 1 Autoimmunity study for its CAR T-cell therapy ...

At the time of writing, FATE stock has soared more than 17% on news that Steve Cohen and his Point 72 hedge fund have taken a 5% passive stake in the biotech company. Fate Therapeutics is working ...